<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2179">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132790</url>
  </required_header>
  <id_info>
    <org_study_id>BC-NEO-IIT-SHR1316-SHR6390-RT</org_study_id>
    <nct_id>NCT05132790</nct_id>
  </id_info>
  <brief_title>Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment</brief_title>
  <official_title>Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment for Patients With Triple-negative and Hormone Receptor-positive, HER2-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of stereotactic body&#xD;
      radiation therapy (SBRT) combined neoadjuvant treatment for patients with triple-negative and&#xD;
      hormone receptor-positive, HER2-negative breast cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">October 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR) for TNBC group</measure>
    <time_frame>Up to11 months</time_frame>
    <description>pCR is defined as the absence of residual invasive cancer on resected breast specimen and the sampled regional lymph nodes as shown by hematoxylin-eosin staining after completion of the neoadjuvant treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Residual cancer burden (RCB) 0-I index for HER2-/HR+BC group</measure>
    <time_frame>Up to11 months</time_frame>
    <description>Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. 5 variables are included in a calculation formula to evaluate the total index(0-III), the higher scores mean a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR) forHER2-/HR+BC group</measure>
    <time_frame>Up to11 months</time_frame>
    <description>pCR is defined as the absence of residual invasive cancer on resected breast specimen and the sampled regional lymph nodes as shown by hematoxylin-eosin staining after completion of the neoadjuvant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual cancer burden (RCB) 0-I index for TNBC group</measure>
    <time_frame>Up to11 months</time_frame>
    <description>Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. 5 variables are included in a calculation formula to evaluate the total index(0-III), the higher scores mean a worse outcome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>Up to11 months</time_frame>
    <description>ORR by investigator using RECIST Guideline (Version 1.1)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse reactions（AE） and Serious adverse reactions （SAE)</measure>
    <time_frame>Through study completion, an average of 15 months</time_frame>
    <description>Adverse reactions（AE） and Serious adverse reactions during the study</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2-/HR+BC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1316 at a dose 20mg/kg q3w</intervention_name>
    <description>Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin</description>
    <arm_group_label>TNBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390 at a dose of 150mg orally, daily</intervention_name>
    <description>SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT</description>
    <arm_group_label>HER2-/HR+BC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>radiation therapy for breast cance before surgery.</description>
    <arm_group_label>HER2-/HR+BC</arm_group_label>
    <arm_group_label>TNBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed histologic diagnosis of invasive adenocarcinoma of the breast&#xD;
&#xD;
          -  ER, PR and HER2 testing, and&#xD;
&#xD;
          -  TNBC patients （ HER2-neu 0-1+ by IHC or FISH-negative by ASCO CAP guidelines）&#xD;
&#xD;
          -  ER-positive and HER2-negative breast cancer&#xD;
&#xD;
          -  tumor measuring ≥2 cm in maximal diameter as measured by any available standard of&#xD;
             care imaging (mammogram, breast ultrasound, breast MRI)&#xD;
&#xD;
          -  Any nodal status&#xD;
&#xD;
          -  ECOG Performance Status of 0 -1&#xD;
&#xD;
          -  Screening laboratory values must meet the following criteria:&#xD;
&#xD;
             i. Absolute neutrophil count (ANC) ≥1.5 × 109/L ii. Platelets ≥100 × 109/L iii.&#xD;
             Hemoglobin ≥ 10.0 g/dl for TNBC, ≥ 10.0 g/dl for HR+/HER2-BC iv. Serum creatinine ≤1.5&#xD;
             x upper limit of normal (ULN) v. AST ≤ 2.5 xULN vi. ALT ≤ 2.5 x ULN vii. Total&#xD;
             bilirubin ≤ 2.5 xULN viii left ventricular ejection fraction ≥ 50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any kind of prior treatment for breast cancer, including chemotherapy, radiotherapy,&#xD;
             endocrine therapy and so on&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Pregnant and lactating women;&#xD;
&#xD;
          -  distant metastasis&#xD;
&#xD;
          -  patients who have participated in other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nan Niu, MD</last_name>
    <phone>+8618940256668</phone>
    <email>niunannancy@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cai-Gang Liu, MD</last_name>
    <phone>+8618940256668</phone>
    <email>niunannancy@163.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Caigang Liu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Findings from this study will indicate whether stereotactic body radiation therapy (SBRT) combined neoadjuvant treatment for patients with triple-negative and hormone receptor-positive, HER2-negative breast cancer is safe and effective.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

